Impact of primary cancer history and molecular landscape in therapy-related myeloid neoplasms

t-MN exhibits distinct clinical and molecular profiles according to prior malignancy type. Intriguingly, our analysis reveals a distinct latency pattern in <i>TP53</i>-mutated cases, suggesting unique leukemogenic dynamics. Moreover, IPSS-M proved highly accurate in predicting t-MDS survival. Integrating molecular data into prognostic models enhances risk stratification and informs therapeutic strategies, potentially improving outcomes for t-MN patients. Further studies are needed to validate these findings and refine tailored treatment approaches.